Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - With a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (X-linked) or ARCI Ichthyosis in Subjects Aged ≥6 Years

NCT05295732 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT05295732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05295732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - With a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (X-linked) or ARCI Ichthyosis in Subjects Aged ≥6 Years
Lead sponsor
LEO Pharma
Phase
Phase 3
Overall status
Completed
Start date
June 21, 2022
Completion date
September 23, 2024
Enrollment
153 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

ichthyosis